Pay in 4 interest-free payments of $6.19 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Preferential accumulation at injury sites suggests active homing mechanisms or increased vascular permeability and tissue binding at sites of damage, though specific mechanisms governing injury-site localization remain under investigation
Bismah Irfan, MD, book a consultation with IVitality MD
Neither AOD 9604 nor retatrutide holds a Marketing Authorisation from the MHRA, meaning selling or supplying them with therapeutic claims in the UK is illegal under the Human Medicines Regulations 2012
103.66 SAVE 5.46 Including VAT, plus shipping costs
US$ 22.53
US$ 27.49
US$ 25.56
